SCHEMBL3979308

SCHEMBL3979308

COc1c(Br)ccc(NC(=O)OC(C)(C)C)c1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
HTT P42858 1/20 0.36
HSD17B10 Q99714 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
METAP2 P50579 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
GFER P55789 1/20 0.35
RECQL P46063 1/20 0.35
ATR Q13535 1/20 0.34
BRD9 Q9H8M2 1/20 0.34
AAK1 Q2M2I8 1/20 0.34
MAPT P10636 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5305447 0.85 ALDH1A1 (0.42) MEN1KMT2AHTTHSD17B10ALDH1A1
SCHEMBL3988441 0.83 BRD9 (0.38) MEN1KMT2ANPC1RAB9AHTT
SCHEMBL34472418 0.82 CYP17A1 (0.39) MEN1KMT2ANPC1RAB9AHTT
SCHEMBL3983959 0.82 ATR (0.38) MEN1KMT2ANPC1RAB9AHTT
SCHEMBL3987667 0.81 SYK (0.42) KMT2ANPC1RAB9AHTTSMN1; SMN2
SCHEMBL19253007 0.81 AAK1 (0.57) MEN1KMT2AAAK1
SCHEMBL14494974 0.80 KDM4E (0.40) MEN1KMT2AHSD17B10ALDH1A1KDM4E
SCHEMBL21468506 0.80 KCNQ4 (0.40) MEN1KMT2ANPC1RAB9AHTT
SCHEMBL25527678 0.79 RAB9A (0.44) MEN1KMT2ANPC1RAB9AHTT
SCHEMBL29197070 0.78 MAPT (0.37) MEN1KMT2ANPC1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092065-A1 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES REMIX THERAPEUTICS INC (US) 2025-03-20 US disclosed
WO-2023133217-A1 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES REMIX THERAPEUTICS INC. (US) 2023-07-13 WO disclosed
WO-2023133217-A1 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES REMIX THERAPEUTICS INC. (US) 2023-07-13 WO disclosed
US-7491718-B2 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES (US) 2009-02-17 US disclosed
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity ABBVIE INC. 2004-08-26 US disclosed
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP MEN1 580/4885KMT2A 647/4885NPC1 4400/4885
US-20250092065-A1 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SNRPA, SNRPB2, HNRNPAB MEN1 2772/4885KMT2A 1429/4885NPC1 1348/4885
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP MEN1 580/4885KMT2A 647/4885NPC1 4400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.